Diurnal IOP curves have limited value in patients with POAG

Article

Diurnal IOP curves have limited value in clinical practice for patients with primary open-angle glaucoma (POAG), according to a newly published study.

Diurnal IOP curves have limited value in clinical practice for patients with primary open-angle glaucoma (POAG), according to a study newly published in Ophthalmology. A single curve poorly characterizes fluctuations in IOP, and patterns cannot be reproduced from month to month, researchers say.

French researchers conducted a database study of 92 patients who had POAG. The patients had their diurnal IOP curve measurements taken 4 times, 6 months apart. Goldmann applanation tonometry had been recorded with patients in the sitting position at 9 am, 10 am, 11 am, noon, 2 pm, 3 pm, 4 pm and 5 pm. Intraclass correlation coefficients (ICCs) were used to measure intervisit agreement of IOP by time point and of diurnal IOP curve parameters, including mean, standard deviation, range, maximum, maximum hour, minimum and minimum hour.

The researchers found generally poor agreement of between-visit agreement of IOP values at each time point. ICCs were 0.26 to 0.77 in all patients. Also, using the first diurnal IOP curve to predict the risk of IOP fluctuations during the 3 subsequent curves was of limited value. "Only 6.4% of the patients with an IOP range ≥30% of the mean IOP on the first curve presented similar fluctuations on the 3 subsequent curves; 77.1% of the patients who did not have an IOP range ≥30% of the mean IOP on the first curve had an IOP range ≥30% of the mean IOP on at least 1 of the 3 subsequent curves," they wrote.

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.